The bridging study’s main objective is to assess the objective response rate of the therapy in subjects with R/R FL with EZH2 mutations. Credit: Chay_Tee/Shutterstock.
The software provides a database of clinical images to help healthcare professionals diagnose skin conditions. Credit: Evgeniy Kalinovskiy/Shutterstock. The Menarini Group, along with its subsidiary
Johnson & Johnson developed the dual-acting monoclonal antibody. Credit: Skorzewiak/Shutterstock. Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its
The therapy is undergoing Phase I clinical development. Credit: Alex_Traksel/Shutterstock. Servier and Black Diamond Therapeutics have signed a licensing agreement for a targeted therapy, BDTX-4933,
Pfizer is set to obtain all net proceeds from the offering. Credit: © 2025 Pfizer Inc. All rights reserved. Pfizer has divested its entire residual
The alliance combines the strengths of OBT’s platform with Roche’s expertise in drug development. Credit: PowerUp/Shutterstock. Oxford BioTherapeutics (OBT) has entered a multi-year partnership with
The company is focused on developing treatments for acute central nervous system injuries. Credit: Jo Panuwat D/Shutterstock. The US Patent and Trademark Office (USPTO) has
Insight’s ophthalmic imaging bioresource includes 35 million images of the eye. Credit: PeopleImages.com – Yuri A/Shutterstock. Moorfields Eye Hospital’s Insight Health Data Research Hub and
The company is progressing gene editing medicine through a multi-centre, open-label, Phase I/II trial. Credit: metamorworks/Shutterstock. Arbor Biotechnologies has closed $73.9m in a Series C
The agreement involves the development of the first oral glucagon-like peptide-1/glucagon dual agonist to offer obesity treatments. Credit: fizkes/Shutterstock. Opko Health and Entera Bio have